regarding efficacy as reflected in that letter.

  Regulatory approvals and filings in the EU and Japan:

  DATE DATE PRODUCT DESCRIPTION OF EVENT APPROVED SUBMITTED

    Xalacom Approval in Japan for the treatment of glaucoma January 2010 —

    Prevenar 13 Approval in the EU for prevention of invasive pneumococcal disease in December 2009 — Infant infants and young children

    Prevenar 7 Approval in Japan for prevention of invasive pneumococcal disease in December 2009 — Infant infants and young children

    Prevenar 13 Application submitted in Japan for prevention of invasive pneumococcal — December 2009 Infant disease in infants and young children

    Sutent Application submitted in the EU for treatment of pancreatic neuroendocrine — December 2009 tumor

    Xiaflex Application submitted in the EU for treatment of Dupuytren’s contracture — December 2009

    atorvastatin Application submitted in the EU for type II variation for atorvastatin calcium — November 2009 calcium (SORTIS and associated names) for pediatric hyperlipidemia/

dyslipidemia

    Geodon Approval in the EU for pediatric bipolar disorders September 2009 —

    Toviaz Application submitted in Japan for overactive bladder — September 2009

    Genotropin Application submitted in the EU for adult growth hormone deficiency (Mark — September 2009 VII multidose disposable device)

    Lyrica Application submitted in Japan for neuropathic pain — August 2009

    Caduet Approval in Japan for concomitant hypertension and hypercholesterolemia July 2009 —

    Celebrex Approval in Japan for treatment of lower-back pain June 2009 —

    Fablyn Approval in the EU for the treatment of osteoporosis February 2009 — (lasofoxifene)

    Zithromac Approval in Japan for bacterial infections January 2009 —

    Lyrica Application submitted in Japan for the treatment of pain associated with — May 2008 post-herpetic neuralgia

  In February 2009, Fablyn received approval in Europe for the treatment of osteoporosis. Subsequently, following a strategic review, we decided to explore strategic options for Fablyn, including out-licensing or sale.

In April 2009, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion, recommending that the European Commission not add an indication for the treatment of fibromyalgia to the marketing authorization for Lyrica. The CHMP was of the opinion that the benefits of Lyrica in the treatment of fibromyalgia did not outweigh its risks. On July 23, 2009, the CHMP confirmed the negative opinion for the treatment of fibromyalgia for Lyrica. As a result, this indication will not be added to the marketing authorization for Lyrica in the EU. Lyrica remains approved in Europe for the indications of neuropathic pain, adjunctive treatment of epilepsy and GAD.

We no longer are seeking approval in the EU for Celsentri (maraviroc) for the treatment of HIV in treatment-naïve patients. Celsentri (maraviroc) remains approved in the EU for use in combination with other antiretroviral medicinal products for treatment-experienced adult patients with only CCR5-tropic HIV-1 detectable.

  Late-stage clinical trials for